Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Leukemia

 

CPX-351 Versus 7+3 for Older Patients (2651)
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Closed;   Study ID: NCT01696084

GS-1101 (CAL-101) for Previously Treated Chronic Lymphocytic Leukemia (FH 2693)
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Closed;   Study ID: NCT01659021

Combination Chemotherapy for Young Patients With Newly Diagnosed T-Cell ALL (COG AALL0434)
Intensified Methotrexate, Nelarabine (Compound 506U78 IND # 52611) and Augmented BFM Therapy in Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia

Investigator: Blythe Thomson, MD;   Conditions: Acute Lymphoid Leukemia (ALL);    Status: Recruiting;   Study ID: NCT00408005

High Throughput Drug Sensitivity Assay for Selecting Treatment for Relapsed/Refractory AML (8003)
Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01872819

Safety Study of SGN-CD33A Acute Myeloid Leukemia (2690)
A Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Recruiting;   Study ID: NCT01902329

Adoptive Immunotherapy for Relapsed AML, MDS, or CML (FH 2498)
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML

Investigator: Merav Bar, MD;   Conditions: Acute Myeloid Leukemia (AML); Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Leukemia;    Status: Recruiting;   Study ID: NCT01640301

Cord Blood Cell Infusion Post Chemotherapy for AML (2584)
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Induction Chemotherapy (FLAG) in Patients with Relapsed/Refractory AML

Investigator: Colleen Delaney, MD, MSc;   Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia;    Status: Recruiting;   Study ID: NCT01701323

Tosedostat with Cytarabine or Decitabine for AML
A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01567059

CSL362 for CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01632852

Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients (2572)
A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Recruiting;   Study ID: NCT01756677

Decitabine + Mitoxantrone Hydrochloride, Etoposide, and Cytarabine for AML or MDS (2652)
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01729845

Radioimmunotherapy + SCT for Advanced AML, ALL, or MDS
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate

Investigator: John M. Pagel, MD;   Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT00988715

Decitabine Followed by Idarubicin and Cytarabine for AML or MDS
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML

Investigator: Derek L. Stirewalt, MD;   Conditions: Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01607645

Umbilical Cord Blood Transplant w/wo Ex-Vivo Expanded Cord Blood Progenitor Cells
Multi-center, Open-label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-the-shelf ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies

Investigator: Colleen Delaney, MD;   Conditions: Leukemia;    Status: Pending;   Study ID: NCT01690520

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride for Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) (2734)
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Recruiting;   Study ID: NCT02044796

AMG 232 for Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT02016729

Outpatient Induction Chemotherapy for Newly Diagnosed AML or MDS (7910)
Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Investigator: Pamela S. Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01807091

Liposomal Cytarabine-Daunorubicin CPX-351 for Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (2642)
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

Investigator: Roland B. Walter, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01804101

Decitabine and Cytarabine for Newly Diagnosed AML, High Risk MDS or MPN (9019)
Decitabine plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MDS);    Status: Recruiting;   Study ID: NCT02121418

IGN523 for Relapsed or Refractory Acute Myeloid Leukemia (20140188)
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT02040506

Selecting a Favorable KIR Donor in Unrelated HCT for AML (2484)
KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor

Investigator: Ann Woolfrey, MD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Recruiting;   Study ID: NCT01288222

Standard of Care w/wo Midostaurin to Prevent Relapse Post Transplant (9037)
A Phase II, Randomized, Comparative Trial of Standard of Care, with or without Midostaurin to Prevent Relapse following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia

Investigator: Bart Scott, MD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01883362

SGN-CD33A for Newly Diagnosed Acute Myeloid Leukemia (9233)
A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia (AML)

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT02326584

Telemonitoring Outpatient Management Post Intensive Chemotherapy (9105)
Integrating a Telemonitoring Device into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study

Investigator: Roland Walter, MD;   Conditions: Leukemia, Myelodysplastic Syndromes , Myeloproliferative Syndromes;    Status: Recruiting;   Study ID: NCT02226497

ABT-199 + Low-Dose Cytarabine Acute Myelogenous Leukemia (9237)
A Phase 1/2 Study of ABT-199 in Combination with Low-Dose Cytarabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are >= 65 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT02287233

Idelalisib + Bendamustine and Rituximab for Untreated CLL (9064)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Recruiting;   Study ID: NCT01980888

Dasatinib Versus Imatinib for Chronic Phase Chronic Myeloid Leukemia
An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib

Investigator: Vivian G. Oehler, MD;   Conditions: Chronic Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01593254

Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia

Investigator: Rebecca Gardner, MD;   Conditions: CD19+ Leukemia;    Status: Recruiting;   Study ID: NCT02028455